TOP TEN

CEO : Eric Ostertag

Leveraging its gene engineering platform technologies , Poseida Therapeutics is a clinical-stage biopharmaceutical company that strives to bring better treatments to patients with serious diseases .

Poseida Therapeutics ’ fourgene engineering platforms include piggyBac , CAS-Clover , Gene Delivery , and CAR-T Tools to provide a safer , more durable , and more efficient suite of treatments .

Poseida Therapeutics became public in July 2020 , and is a spinout organisation from its parent company , Transposagen , an early leader in the development of gene engineering technology .

CEO : John Evans

DNA has four types of bases : adenine ( A ), cytosine ( C ), guanine ( G ), and thymine ( T ). The human genome consists of more than three billion pairs ( adenine and thymine , and cytosine and guanine ). If point mutation occurs in the genome , proteins can become dysfunctional or missing altogether which causes diseases .

Beam Therapeutics , a pioneer in the use of CRISPR base editing , is harnessing its groundbreaking technology to “ make permanent , specific edits to single bases in DNA and RNA , without cutting the strands .” In doing so , Beam Therapeutics is developing a new class of precision-genetics medicine by “ combining precision targeting of the genome with precision control of editing outcomes .”

technologymagazine . com 151